Regional media highlights UC pancreatic cancer vaccine trial
Regional media highlighted the University of Cincinnati Cancer Center being the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.
Davendra Sohal, MD, site principal investigator, said this trial builds on the same mRNA technology that was used to develop vaccines for COVID-19.
"In addition to the standard surgery and chemotherapy, they also get this very personalized vaccine created using their own tumor profile,” Sohal, associate director for clinical research at the Cancer Center and professor of internal medicine in UC’s College of Medicine, told Local 12.
The vaccine is developed in about four to six weeks while patients are recovering from surgery, and patients are then given six weekly injections of the vaccine. Following six months of standard chemotherapy, patients then receive six more vaccine injections as boosters.
In the Phase 1 trial, Sohal said eight out of 32 patients were completely cured of their cancer.
Watch or read the Local 12 story.
Read the Becker's Hospital Review story.
Read the WDRB Louisville story.
For more information on the trial, please call 513-584-7698 or email cancer@uchealth.com.
Featured photo at top of a vaccine being administered. Photo/National Cancer Institute/Unsplash.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.